ARWR News

Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.

ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the companys first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease...

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference September 9-11, 2026 Type: Fireside Chat Presentation Date/Time: September 10, 2026, 10:55 am EDT Morgan Stanley...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) are the among first in the European Union to have a new treatment option to reduce dangerously high levels of triglycerides...

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.